Earnings History Data for TCR2 Therapeutics Inc. (TCRR) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
TCR2 Therapeutics Inc.
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. Its product candidate includes TC-210, TC-220, TC-410, TC-110 and TC-310 which are in clinical stage. TCR2 Therapeutics Inc. is based in Cambridge, Massachusetts.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23-03-2023 | PM | 6:45 AM ET (Mar 23) |
TCRR | TCR2 Therapeutics | 60.00 | -1.56 | -0.80 | 0.00 | TCR2 Therapeutics GAAP EPS of -$1.56 misses by $0.74 [3/23/2023 7:59 AM] |
1.40 | -0.07 (-4.76%) |
0.0 | 0.0 (0.00%) |
0.82 - 3.88 | 319,420 | 360,000 | 0 | |
| 08-11-2022 | PM | TCRR | TCR2 Therapeutics | 54.00 | -0.79 | -0.83 | 0.00 | TCR2 Therapeutics GAAP EPS of -$0.79 beats by $0.06 [11/8/2022 9:06 AM] |
1.36 | -0.02 (-1.45%) |
0.0 | 0.0 (0.00%) |
1.32 - 7.36 | 165,365 | 230,000 | 0 | ||
|
||||||||||||||||||
| 08-08-2022 | PM | TCRR | TCR2 Therapeutics | 125.00 | -0.82 | -0.77 | 0.00 | TCR2 Therapeutics GAAP EPS of -$0.82 misses by $0.02 [8/8/2022 6:59 AM] |
3.36 | 0.08 (2.44%) |
3.28 | 0.0 (0.00%) |
2.06 - 19.03 | 176,112 | 180,000 | 2,273 | ||
| 22-03-2022 | PM | TCRR | TCR2 Therapeutics | 105.00 | -0.72 | -0.75 | 0.00 | TCR2 Therapeutics GAAP EPS of -$0.72 beats by $0.04 [3/22/2022 6:59 AM] |
3.20 | 0.45 (16.36%) |
2.96 | 0.21 (7.64%) |
2.36 - 25.22 | 877,759 | 744,720 | 0 | ||
| 10-11-2021 | PM | TCRR | TCR2 Therapeutics | 271.00 | -0.69 | -0.65 | 0.00 | TCR2 Therapeutics EPS misses by $0.02 [11/10/2021 6:59 AM] |
6.97 | -0.12 (-1.69%) |
0.0 | 0.0 (0.00%) |
6.29 - 35.86 | 871,365 | 730,000 | 0 | ||
| 05-08-2021 | PM | TCRR | Tcr2 Therapeutics Inc. | 498.00 | -0.64 | -0.60 | 0.00 | TCR2 Therapeutics EPS misses by $0.03 [8/5/2021 7:34 AM] |
13.71 | 0.94 (7.36%) |
12.76 | -0.01 (-0.08%) |
12.15 - 35.86 | 301,938 | 280,000 | 50 | ||
| 13-05-2021 | PM | 6:45 AM ET (May 13) |
TCRR | TCR2 Therapeutics Inc. | 737.58 | -0.58 | -0.55 | -0.65 | TCR2 Therapeutics EPS misses by $0.05 [5/13/2021 6:54 AM] |
19.01 | -0.28 (-1.45%) |
19.01 | 0.0 (0.00%) |
8.71 - 35.86 | 324,804 | 290,000 | 3,421 | |
| 11-03-2021 | PM | 6:45 AM ET (Mar 11) |
TCRR | Tcr2 Therapeutics Inc. | 882.00 | -0.55 | -0.57 | 0.00 | TCR2 Therapeutics EPS beats by $0.02 [3/11/2021 7:27 AM] |
27.92 | 0.26 (0.94%) |
27.66 | 0.0 (0.00%) |
5.84 - 35.86 | 254,148 | 356,638 | 8,307 | |
|
||||||||||||||||||
| 12-08-2020 | PM | TCRR | TCR2 Therapeutics Inc. | 559.37 | -0.67 | -0.61 | -0.46 | TCR2 Therapeutics EPS misses by $0.03 [8/12/2020 7:28 AM] |
17.90 | -0.08 (-0.44%) |
18.34 | 0.36 (2.00%) |
5.84 - 21.06 | 142,166 | 257,727 | 245 | ||
|
|
||||||||||||||||||